

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF: Akihiro TAKEMIYA, et al.

SERIAL NO: 10/589,130

GAU: 1625

FILED: January 16, 2007

EXAMINER: CHANG, CELIA C.

FOR: INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97**

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

**REFERENCES**

- ☒ Submitted herewith is a European Office Action for the Examiner's consideration. The references cited therein were previously filed on August 11, 2006 and August 31, 2009.

**RELATED CASES**


- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.

**CERTIFICATION**

- ☒ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this statement.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, L.L.P.



Richard D. Kelly

Registration No. 27,757

Customer Number  
22850  
Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 02/10)

**Stefan Koschmieder**  
**Registration No. 50,238**